Microbiological Aspects of Chronic Prostatitis | CMAC

Microbiological Aspects of Chronic Prostatitis

Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(1):4-17

​ Naber K., Sukhorukova M.V.
chronic prostatitis chronic pelvic pain syndrome Meares-Stamey test microbiological diagnosis colonization infection
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(1):4-17

Abstract

Chronic prostatitis/chronic pelvic pain syndrome is one of the most common diseases in urology which is difficult to diagnose and treat. According to current international guidelines, choice of approach to the management of patients with chronic prostatitis depends on localization of pathological process in urinary tract, clinical type of the disease, and etiology. This paper reviews modern microbiological aspects of prostatitis, as well as its epidemiology and classification. The role of Gram-positive cocci and other possible pathogens as causative agents of chronic prostatitis is also discussed.

  • 1. Krieger J.N. Classification, epidemiology and implications of chronic prostatitis in North America, Europe and Asia. Minerva Urol Nefrol 2004; 56:99-107.
  • 2. Nickel C.J. Prostatitis: evolving management strategies. Urol Clin North Am 1999; 26:737-57.
  • 3. Meares E.M., Stamey T.A. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968; 5:492-518.
  • 4. Moon T.D. Questionnaire survey of urologists and primary care physicians’ diagnostic and treatment practices for prostatitis. Urology 1997; 50:543-7.
  • 5. Roberts R.O., Jacobson D.J., Girman C.J., et al. Prevalence of prostatitis-like symptoms in a community based cohort of older men. J Urol 2002; 168:2467-71.
  • 6. Alexander R.B. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome. Ann Intern Med 2004; 141:581-9.
  • 7. Nickel J.C., Downey J., Hunter D., Clark J. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol 2001; 165:842-5.
  • 8. Collins M.M., Stafford R.S., O’Leary M.P., Barry M.J. How common is prostatitis? A national survey of physician visits. J Urol 1998; 159:1224-8.
  • 9. Boyle P., Robertson C., Mazetta C., et al.; UrEpik Study Group. The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int 2003; 92:409-14.
  • 10. Rizzo M., Marchetti F., Travaglini F., et al. Prevalence, diagnosis and treatment of prostatitis in Italy: a prospective urology outpatient practice study. BJU Int 2003; 92:955-9.
  • 11. Naber K.G., Weidner W. Chronic prostatitis – an infectious disease? J Antimicrob Chemother 2000; 46:157-61.
  • 12. Krieger J.N., Egan K.J., Ross S.O., et al. Chronic pelvic pains represent the most prominent urogenital symptoms of «chronic prostatitis». Urology 1996; 48:715-22.
  • 13. European Association of Urology. Guidelines on chronic pelvic pain, 2003. Available from www.uroweb.org.
  • 14. Набер К. Оптимальная терапия инфекций мочевыводящих путей. Клин микробиол антимикроб химиотер 1999; 1:23-30.
  • 15. Weidner W., Schiefer H.G., Krauss H., et al. Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1461 patients. Infection 1991; 19(Suppl. 3): S119-S125.
  • 16. Naber K.G. Chronic (Bacterial) Prostatitis. Lectures in Hospital Infections. Part Two: Complicated Urinary Tract Infections. London: 2003. P. 13-31.
  • 17. Drach G.W., Fair W.R., Meares E.M., Stamey T.A. Classification of benign diseases associated with prostatic pain: prostatitis or prostatodynia? J Urol 1978; 120:266.
  • 18. Lummus W.E., Thompson I. Prostatitis. Emerg Med Clin North Am 2001; 19:691-707.
  • 19. Nickel J.C., Weidner W. Chronic Prostatitis: Current Concepts and Antimicrobial Therapy. Infect Urol 2000; 13(Suppl.):22-8.
  • 20. Nickel J.C. Prostatitis: myths and realities. Urology 1998; 51:362-6.
  • 21. Krieger J.N., Nyberg L.M., Nickel J.C. for the International Prostatitis Collaborative Network. NIH consensus definition and classification of prostatitis. JAMA 1999; 282:236-7.
  • 22. National Institutes of Health. Summary Statement. National Institutes of Health/National Institutes of Diabetes and Digestive and Kidney Diseases workshop on chronic prostatitis. Bethesda, USA. 1995.
  • 23. Nickel J.C. Prostatitis: lessons from the 20th century. Br J Urol 2000; 85:179-84.
  • 24. Domingue G.J. Sr., Hellstrom W.J. Prostatitis. Clin Microbiol Rev 1998; 11:604-13.
  • 25. Naber K.G. The role of quinolones in the treatment of chronic bacterial prostatitis. Infection 1991; 19(Suppl. 3):S170-S177.
  • 26. Nickel J.C. Chronic prostatitis: an infectious disease? Infect Urol 2000; 13:31-8.
  • 27. Bundrick W., Heron S.P., Ray P., et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 2003; 62:537-41.
  • 28. Nickel J.C., Costerton J.W. Coagulase-negative staphylococcus in chronic prostatitis. J Urol 1992; 147:398-400.
  • 29. Domingue G.J. Microbiological aspects of prostatitis. In: Textbook on prostatitis. Oxford: ISIS Medical Media Ltd.; 1999. P. 69-81.
  • 30. Stamey T.A. Comment to Fawler&Mariano. J Urol 1984; 132:471-3.
  • 31. Arakawa S., Matsui T., Gohji K., et al. Prostatitis – the Japanese viewpoint. Int J Antimicrob Agents 1999; 11:201-3.
  • 32. Naber K.G. Prostatitis, Epididymitis and Orchitis. London: Mosby; 1999. p. 58.1-58.6.
  • 33. Nickel J.C. The Pre and Post Massage Test (PPMT): a simple screen for prostatitis. Tech Urol 1997; 3:38-43.
  • 34. Nickel J.C. Prostatitis. Is it time to change the rules? Contemporary urology 2000: 64-84.
  • 35. Schaeffer A.J., Wendel E.F., Dunn J.K., Grayhack J.T. Prevalence and significance of prostatic inflammation. J Urol 1981; 125:215-9.
  • 36. Nickel J.C., Alexander R.B., Schaeffer A.J., et al. Leukocytes and bacteria in men with chronic prostatitis/ chronic pelvic pain syndrome compared to asymptomatic controls. J Urol 2003; 170:818-22.
  • 37. Li L.J., Shen Z.J., Lu Y.L., Fu S.Z. The value of endotoxin concentrations in expressed prostatic secretions for the diagnosis and classification of chronic prostatitis. BJU Int 2001; 88:536-9.
  • 38. Wagenlehner F.M., Weidner W., Sorgel F., Naber K. The role of antibiotics in chronic bacterial prostatitis. Int J Antimicrob Agents 2005; 26:1-7.
  • 39. Nickel J.C. Classification and diagnosis of prostatitis: a gold standard? Andrologia 2003; 35:160-7.
  • 40. Nickel J.C., Moon T. Chronic bacterial prostatitis: an evolving clinical enigma. Urology 2005; 66:2-8.
  • 41. Andreu A., Stapleton A.E., Fennell C., et al. Urovirulence determinants in Escherichia coli strains causing prostatitis. J Infect Dis 1997; 176:464-9.
  • 42. Naber K.G. Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents 2002; 20:18-27.
  • 43. Naber K.G., Busch W., Focht J. Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. Int J Antimicrob Agents 2000; 14:143-9.
  • 44. Krieger J.N., Ross S.O., Limaye A.P., Riley D.E. Inconsistent localization of gram-positive bacteria to prostate-specific specimens from patients with chronic prostatitis. Urology 2005; 66:721-5.
  • 45. Krieger J.N., Riley D.E. Bacteria in the chronic prostatitis-chronic pelvic pain syndrome: molecular approaches to critical research questions. J Urol 2002; 167:2574-83.
  • 46. Krieger J.N., Riley D.E., Roberts M.C., Berger R.E. Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. J Clin Microbiol 1996; 34:3120-8.
  • 47. Skerk V., Krhen I., Lisic M., et al. 4.5- or 6.0-gram dose in the treatment of patients with chronic prostatitis caused by Chlamydia trachomatis – a randomized study. J Chemother 2004; 16:408-10.
  • 48. Skerk V., Schonwald S., Krhen I., et al. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents 2003; 21:457-62.
  • 49. Skerk V., Schonwald S., Krhen I., et al. Aetiology of chronic prostatitis. Int J Antimicrob Agents 2002; 19:471-4.
  • 50. Smelov V., Perekalina T., Artemenko N., et al. Chlamydia trachomtis survival in the presence of two fluoroqinolones (lomefloxacin versus levofloxacin) on patients with chronic prostatitis syndrome. Andrologia 2005; 37:61-4.
  • 51. Domingue G.J., Human L.G., Hellstrom W.J. Hidden microorganisms in “abacterial” prostatitis/prostatodinia. J Urol 1997; 157:952.
  • 52. Riegel P., Ruimy R., de Briel D., et al. Corynebacterium seminale sp. nov., a new species associated with genital infections in male patients. J Clin Microbiol 1995; 33:2244-9.
  • 53. Benson P.J. Cytomеgalovirus prostatitis. Urology 1992; 40:165-7.
  • 54. Doble A., Harris J.R., Taylor-Robinson D. Prostatodynia and herpes simplex virus infection. Urology 1991; 38:247-8.
  • 55. Shortliffe L.M., Sellers R.G., Schachter J. The characterization of nonbacterial prostatitis: search for an etiology. J Urol 1992; 148:1461-6.
  • 56. Ostaszewska I. Chlamydia trachomatis as a probable cause of prostatitis. Int J STD/AIDS 2000; 11:482-3.
  • 57. Mardh P.A., Ripa K.T., Colleen S., et al. Role of Chlamydia trachomatis in non-acute prostatitis. Br J Vener Dis 1978; 54:330-4.
  • 58. National guideline for the management of prostatitis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect 1999; 75(Suppl. 1):S46-S50.
  • 59. Krieger J.N., Ross S.O., Berger R.E., Riley D.E. Cryptic microorganisms and prostatitis. In: Textbook on prostatitis. 1999. p. 139-148.
  • 60. Skerk V., Schonwald S., Krhen I., et al. Comparative analysis of azithromycin and clarithromycin efficacy and tolerability in the treatment of chronic prostatitis caused by Chlamydia trachomatis. J Chemother 2002; 14:384-9.
  • 61. Skerk V., Schonwald S., Krhen I., et al. Azithromycin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. J Chemother 2001; 13:664-5.
  • 62. Smelov V., Gorelov A., Smelova N., Krylova T. Single-drug or combined antibacterial therapy in the treatment of patients with chronic prostatitis and Chlamydia trachomatis? Int J Antimicrob Agents 2004; 23(Suppl. 1): S83-S87.
  • 63. Weidner W., Diemer T., Huwe P., et al. The role of Chlamydia trachomatis in prostatitis. Int J Antimicrob Agents 2002; 19:466-70.
  • 64. Krieger J.N., Riley D.E. Prostatitis: what is the role of infection. Int J Antimicrob Agents 2002; 19:475-9.
  • 65. Potts J.M., Sharma R., Pasqualotto F., et al. Association of Ureaplasma urealyticum with abnormal reactive oxygen species levels and absence of leukocytospermia. J Urol 2000; 163:1775-8.
  • 66. Ohkawa M., Yamaguchi K., Tokunaga S., et al. Ureaplasma urealyticum in the urogenital tract of patients with chronic prostatitis or related symptomatology. Br J Urol 1993; 72:918-21.
  • 67. Brook I. Urinary tract and genito-urinary suppurative infections due to anaerobic bacteria. Int J Urol 2004; 11:133-41.
  • 68. Nagy E., Szoke I., Torok L., Pajor L. The role of anaerobic bacteria in prostatitis. Adv Exp Med Biol 2000; 485:289-99.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared